Vnitr Lek 2009, 55(4):331-340

Pharmacoeconomy of diabetes mellitus - trends in the Czech Republic

P. Horák1,2
1 Všeobecná zdravotní pojišťovna ČR Praha, ředitel MUDr. Pavel Horák, CSc., MBA
2 Farmakologický ústav 1. lékařské fakulty UK Praha, přednosta prof. MUDr. František Perlík, DrSc.

Since 2002, we found relatively stable number of diabetes mellitus cases among clients of General Health Insurance Company of the Czech Republic. This means, after calculating incidence rate with respect to decline in total numbers of insured during the same period, a 6% increase in real incidence rate. On the doctors side, outpatient, mostly private diabetologists have about the same capacity of their offices, 2.9 physicians (WTE)/100 000 citizens over the last years. Analysis of costs and volume of services provided, clearly demonstrate, that diabetology is medical specialization of a great importance not only from the point of view of number of patients and services provided but also of its influence on the overall health care costs. Data show not only higher average expenses for treatment of patients with diabetes mellitus compared to average expenses incurred for treatments of all other diagnoses, but show also a crucial relationship of costs with presence or absence of diabetes mellitus complications. Monies spend by the medical insurance system and also and more importantly health profit to patients can thus be substantially influenced via improvements in organization of care, via higher involvement, compliance of patients to the treatment and to necessary change in their lifestyles and last but not least via increase in quality of care. Cost control can be achieved by strengthening the role of pharmacoeconomics in decisions making processes of health insurance companies, importance of which is demonstrated on the past developments on drug market in the Czech Republic. General Health Insurance Company will target these goals in coming years and in its business plans will also include expected increases of costs for organization of care and for higher renumeration of physicians as well.

Keywords: diabetes mellitus; pharmacoeconomy; consumption of medical services; medical insurance

Received: February 9, 2009; Published: April 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Horák P. Pharmacoeconomy of diabetes mellitus - trends in the Czech Republic. Vnitr Lek. 2009;55(4):331-340.
Download citation

References

  1. Bartášková D, Kožnarová R, Kvapil M. Předpokládané náklady na terapii diabetes mellitus a jeho pozdních komplikací v ČR - předběžná studie. Vnitř Lék 2005; 51: 304-313.
  2. Kvapil M et al. Kvalita péče o diabetiky v České republice - současnost a budoucnost. Předneseno na Diabetologických dnech v Luhačovicích v dubnu 2008. Postgrad Med 2009 (v tisku).
  3. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29: 1963-1972. Go to original source... Go to PubMed...
  4. Rosenstock J. Reflecting on type 2 diabetes prevention: more questions than answers! Diabetes Obes Metab 2007; 9 (Suppl 1): 3-11. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.